Novo Nordisk Faces Legal Shift in US Gender Policy
Novo Nordisk, an obesity drugmaker, opts out of its global gender representation initiative in the U.S. due to President Trump’s executive orders halting diversity efforts. The company's U.S. operations will no longer aim for 45% gender representation by 2025, unlike their global counterparts.
- Country:
- Denmark
Obesity drugmaker Novo Nordisk announced a strategic shift on Wednesday, opting to drop its gender representation goals in the United States. This decision follows executive orders from President Donald Trump, which halt diversity, equity, and inclusion efforts in businesses.
The company had globally aspired to achieve at least 45% representation for each gender by the end of 2025. However, due to changing legal demands, this initiative will not include Novo Nordisk's U.S. operations.
This move was detailed in the company's first-quarter earnings statement, highlighting the legal landscape's influence on business practices concerning diversity.
(With inputs from agencies.)
Advertisement
Google News